weight regain after stopping glp-1 agonists Trajectory of the body drug discontinuation in the treatment of anti-obesity medications | BMC Medicine The most-read nutrition and obesity

1364.e1

According to a report from clinical research organization Novotech, China has become the second-most-popular country for obesity trials after the U.S., despite only 6% of the population being classified as obese, compared to 31% in Australia and 40% in the U.S

Following the success and approval of tirzepatide (Mounjaro, Eli Lilly, Indianapolis, IN, USA) in 2022 by FDA for treatment of T2DM, the SURMOUNT programme investigated its use as an anti-obesity medication in those without diabetes

In: Standards of Medical Care in Diabetes2016

The recommended daily allowances (RDAs) for total fiber intake for men and women aged 1950 are 38 gram/day and 25 gram/day, respectively

Finally, only one paper examined the effects of these drugs at week 104, and there are limited data on the long-term effects